Revenue
2018
2019
2020
2021
2022
2023
2024
2025
BIOMARIN PHARMACEUTICAL INC (BMRN)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $889.9M | $749.3M | $548.5M | $500.7M | $441.4M | $376.3M | $324.7M | $296.5M |
| Research & development | $921.9M | $747.2M | $746.8M | $649.6M | $628.8M | $628.1M | $715.0M | $696.3M | $610.8M | $661.9M | $634.8M | $461.5M | $354.8M | $302.2M | $214.4M | $147.3M | $115.1M | $93.3M |
| Operating income | $409.5M | $484.2M | $185.8M | $161.0M | −$82.3M | −$43.4M | −$100.5M | −$123.5M | −$14.7M | −$803.4M | −$110.7M | −$92.9M | −$156.0M | −$110.2M | −$33.9M | $544,000 | $16.4M | $39.8M |
| EBITDAderived | $489.0M | $580.6M | $290.2M | $262.9M | $25.7M | $61.7M | $4.8M | −$27.9M | $73.2M | −$706.5M | −$63.5M | −$47.0M | −$120.0M | −$65.9M | $1.2M | $28.3M | $37.4M | $57.4M |
| Net income | $348.9M | $426.9M | $167.6M | $141.6M | −$64.1M | $854.0M | −$23.8M | −$77.2M | −$117.0M | −$630.2M | −$171.8M | −$134.0M | −$176.4M | −$114.3M | −$53.8M | $205.8M | −$488,000 | $30.8M |
| Basic EPSper diluted share | $1.82 | $2.25 | $0.89 | $0.76 | -$0.35 | $4.72 | -$0.13 | -$0.44 | -$0.67 | -$3.80 | -$1.07 | -$0.92 | -$1.28 | -$0.95 | -$0.48 | $2.00 | $0.00 | $0.31 |
| Diluted EPSper diluted share | $1.80 | $2.21 | $0.87 | $0.75 | -$0.35 | $4.50 | -$0.13 | -$0.44 | -$0.67 | -$3.81 | -$1.07 | -$0.92 | -$1.28 | -$0.95 | -$0.48 | $1.73 | $0.00 | $0.29 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 7, 2026Form 4 | Friberg Gregory REVP, Chief R&D Officer | SellCommon Stock | 3.3K | $53.85 | $176.7K | 51.8K |
| Mar 11, 2026Form 4 | Guyer Charles GregEVP, Chief Technical Officer | SellCommon Stock | 16.5K | $60.46 | $996.7K | 80.0K |
| Feb 26, 2026Form 4 | Friberg Gregory REVP, Chief R&D Officer | SellCommon Stock | 6.3K | $60.38 | $382.0K | 37.6K |
| Feb 26, 2026Form 4 | Davis George EricEVP, Chief Legal Officer | SellCommon Stock | 26.1K | $61.36 | $1.60M | 72.5K |
| May 20, 2025Form 4 · 10b5-1 | Burkhart ErinGVP, Chief Accounting Officer | SellCommon Stock | 1.8K | $59.31 | $105.9K | 14.2K |